key: cord-0274155-4t8aowz7
authors: Toulmin, Sushila A.; Bhadiadra, Chaitali; Paris, Andrew J.; Lin, Jeffrey H.; Katzen, Jeremy; Basil, Maria C.; Morrisey, Edward E.; Worthen, G. Scott; Eisenlohr, Laurence C.
title: Type II alveolar cells with constitutive expression of MHCII and limited antigen presentation capacity contribute to improved respiratory viral disease outcomes
date: 2021-03-18
journal: bioRxiv
DOI: 10.1101/2021.03.18.435984
sha: d3a1ed993fc7333af5fe5c5e9b850e86a84b9095
doc_id: 274155
cord_uid: 4t8aowz7

Type II alveolar cells (AT2s) are critical for basic respiratory homeostasis and tissue repair after lung injury. Prior studies indicate that AT2s also express major histocompatibility complex II (MHCII) molecules, but how MHCII expression by AT2s is regulated and how it contributes to host defense remain unclear. Here we show that AT2s express high levels of MHCII independent of conventional inflammatory stimuli, and that selective loss of MHCII from AT2s in mice results in the worsening of respiratory virus disease following influenza and Sendai virus infections. We also find that AT2s exhibit MHCII presentation capacity that is substantially limited in comparison to professional antigen presenting cells. The combination of constitutive MHCII expression and restrained presentation may position AT2s to contribute to lung adaptive immune responses in a measured fashion, without over-amplifying damaging inflammation.

express high levels of MHCII independent of conventional inflammatory stimuli, and that selective loss of MHCII from AT2s in mice results in the worsening of respiratory virus disease following influenza and Sendai virus infections. We also find that AT2s exhibit MHCII presentation capacity that is substantially limited in comparison to professional antigen presenting cells. The combination of constitutive MHCII expression and restrained presentation may position AT2s to contribute to lung adaptive immune responses in a measured fashion, without over-amplifying damaging inflammation.

CD4 + T cell responses are initiated by T cell receptor (TCR) recognition of cognate major histocompatibility complex II (MHCII)/peptide complexes on the surface of antigen presenting cells (APCs). By convention, constitutive MHCII expression is restricted to a few specialized types of cells, including the "professional APCs" B cells, dendritic cells (DCs), and macrophages, as well as thymic epithelial cells (TECs) 1 . In contrast, all other cell types are thought to produce MHCII only in the setting of inflammation, specifically in response to the cytokine interferon-g (IFNg) 2 . However, more recently, an increasing number of other cell types have been shown to express MHCII at homeostasis and to contribute to adaptive immune responses in a variety of settings 3, 4 . These include certain Toulmin, S.A. et al. 3 intestinal ILC3 subsets 5, 6 , which express MHCII independent of IFNg, as well as several nonhematopoietic cell types, such as lymph node stromal cells 7-10 , vascular endothelial cells [11] [12] [13] , and intestinal epithelial cells [14] [15] [16] , whose MHCII production is driven by the basal IFNg present at steady state.

Type II alveolar cells (AT2s) are an additional nonhematopoietic cell type that have been reported to express MHCII at homeostasis in both rodents [17] [18] [19] [20] [21] [22] and humans [23] [24] [25] [26] [27] .

AT2s are epithelial cells present in the lung parenchyma, and their main physiologic functions are to produce surfactant and to serve as stem-like cells in the distal lung 28-31 .

AT2s have also been described to perform several innate immunologic functions 32-34 , and their constitutive MHCII expression suggests that they may participate in lung adaptive immune responses as well. Previous studies of AT2 MHCII function have varied widely, with some concluding that AT2s serve to activate CD4 + T cells 19, 21 and others demonstrating the opposite 20, 26 . As a result, both the MHCII presentation capability of AT2s and the contribution of AT2 MHCII to lung host responses remain unclear. Here we report on the mechanisms regulating homeostatic MHCII expression in AT2s, their antigen presentation capacity, and the impact of AT2 MHCII in vivo.

To verify prior reports of homeostatic AT2 MHCII expression, we assessed MHCII on both mouse and human AT2s by flow cytometry. We found that naïve wild-type C57Bl/6 (B6) AT2s, identified as CD45 -CD31 -EpCAM int (Fig S1) 22 , uniformly express MHCII (Fig Toulmin, S.A. et al. 4 1a). Similarly, healthy human HT2-280 + AT2s 35 express the human MHCII protein HLA-DR (Fig S2a,b) .

We next compared MHCII levels on AT2s to other well-studied MHCII-expressing lung cells in naïve mice. AT2s express MHCII at a magnitude similar to that of lung professional APCs, dendritic cells (DCs) and B cells, and higher than alveolar macrophages (Fig 1b) . Besides AT2s, vascular endothelial cells (ECs) are another nonhematopoietic cell type in the lung that express MHCII at homeostasis 36 . Compared to ECs, AT2 MHCII expression is higher and more homogeneous (Fig 1c) . (Fig 1d, S5a) , and AT2s retained MHCII protein expression to high levels in MHCII -/à B6 CD45.1 mice (Fig 1e) . Thus, AT2s synthesize their own MHCII and do not depend on acquisition of MHCII protein from hematopoietic APCs.

In sum, AT2s represent a unique population of nonhematopoietic lung cells that produce MHCII protein at homeostasis uniformly to high levels, similar to that of professional APCs.

The class II transactivator (CIITA) is the master transcription factor that drives MHCII expression 2 . To determine whether AT2 MHCII expression is dependent on CIITA, we Toulmin, S.A. et al. 5 assessed MHCII in the lungs of Ciita -/mice. Lack of CIITA results in the complete loss of MHCII expression on AT2s, as well as lung DCs and ECs (Fig 1f) . Transcription of CIITA begins at three different promoter sites (pI, pIII, and pIV) depending on cell and context specific stimuli. Recruitment of pI occurs in DCs and macrophages, pIII in B cells and plasmacytoid DCs, and pIV in ILC3s and nonhematopoietic cells 2, 6 . To assess whether AT2 MHCII is dependent on pIV, we evaluated mice lacking just the pIV region within the CIITA locus 39 . AT2s from Ciita pIV -/mice fail to express MHCII, as do ECs, while DCs retain MHCII expression as expected (Fig 1f) .

The recruitment of pIV in all nonhematopoietic cells (except for thymic epithelial cells (TECs)) is thought to require induction by the cytokine IFNg 2 . We evaluated MHCII in mice deficient in IFNg, IFNgR, and the associated downstream pIV-binding transcription factor, STAT1. AT2s retain MHCII expression in Ifng -/-, Ifngr1 -/-, and Stat1 -/mice in a manner similar to DCs and in contrast to ECs, whose MHCII expression is abrogated in the absence of IFNg signaling (Fig 1g) . AT2s, like DCs, exhibit a small reduction in MHCII expression in Stat1 -/mice, indicating that IFNg signaling may upregulate MHCII expression in AT2s, but it is not required for steady state expression.

Besides IFNg, no other cytokine has been shown to be sufficient to induce MHCII expression in nonhematopoietic cells. However, given the IFNg-independent expression of MHCII by AT2s, we also examined the requirement of a broad array of conventional innate and adaptive immune mediators, by assessing Ifnar1 -/-, Ifnar1 -/x Ifngr1 -/-, Myd88 -/-, Stat6 -/-, and germ-free mice. AT2s express MHCII at wild-type levels in all cases ( Fig   S3) , indicating that they also do not require a wide spectrum of other, non-IFNg Toulmin, S.A. et al. 6 inflammatory signals for MHCII expression, including type I IFNs, TLR ligands, IL-1, IL-18, IL-33, Th2 cytokines, and the microbiota.

Altogether, these data demonstrate that AT2 homeostatic MHCII expression is CIITA pIV-dependent, but IFNg-independent. This same transcriptional configuration has been reported for only two other cell types: TECs 40 , which are present in a primary immune organ, and ILC3s 6 , which are immune cells. To our knowledge it has never been described for a cell outside of the immune system.

AT2s possess classical APC characteristics and MHCII antigen processing and presentation machinery We next examined whether AT2s possess mediators of classical MHCII presentation.

By convention, this pathway begins with extracellular antigen acquisition followed by proteolysis in the endocytic compartment 41-43 . To assess these steps, we evaluated the capacity of AT2s to catabolize DQ-Ova, a self-quenched conjugate of ovalbumin protein that fluoresces after receptor-mediated endocytosis and proteolytic digestion. AT2s exhibited a temperature-dependent increase in fluorescence when incubated with DQ-Ova, less so than DCs but similarly to B cells, indicating that they are capable of active antigen uptake and degradation (Fig 2a) . Antigen degradation is mediated by several key enzymes, including asparagine endopeptidase (AEP), gamma-interferon-inducible lysosomal thiol reductase (GILT), and lysosomal/endosomal cathepsin proteases 44 . AT2s have been previously demonstrated to express cathepsins, in particular Cathepsin H (CtsH), which is critical for surfactant protein processing 45, 46 . By RNA-sequencing analysis, we found that naïve mouse AT2s express transcripts for AEP, GILT, and a wide Toulmin, S.A. et al. 7 variety of cathepsin enzymes (Fig S5a) . Furthermore, we directly assessed the activity of two cathepsins in AT2s that play major roles in antigen processing: Cathepsin D (CtsD) and Cathepsin L (CtsL). We found that AT2s exhibited readily detectable activity of both CtsD and CtsL, which was abrogated by specific inhibitors of each enzyme (Fig S5b,c) .

Optimal MHCII presentation also requires appropriate stabilization and trafficking of MHCII by the chaperone protein invariant chain 41-43 . We evaluated invariant chain expression in naïve mouse AT2s by flow cytometry and, consistent with prior reports 22, 38 , found that AT2s express intracellular invariant chain (Fig 2b) .

Classical MHCII processing also depends on the protein H2-M, which catalyzes the removal of the invariant chain peptide remnant CLIP from the MHCII peptide-binding groove in the late endosome and facilitates the loading of higher affinity peptides 41-43 . We evaluated H2-M expression by qPCR, RNA-sequencing analysis, and flow cytometry. In mice, H2-M is a heterodimeric protein composed of one a chain pairing with one of two b chains, b1 or b2 47 ; H2-Mab1 and H2-Mab2 are thought to function similarly 48, 49 . By qPCR, AT2s expressed detectable levels of transcripts encoding the a and b chains of H2-M (Fig   2c) , using b primers that capture both b1 and b2. By flow cytometry AT2s did not express H2-Mab2 protein (Fig 2d) , suggesting that the predominant isoform of H2-M in naïve mouse AT2s is therefore H2-Mab1, which was confirmed by RNA-sequencing analysis ( Fig S5a) . We evaluated H2-M protein function in AT2s by flow cytometric detection of the CLIP/MHCII complex CLIP/I-A b in B6 mice. If H2-M is functionally present, then the number of CLIP/I-A b complexes will be low, as CLIP peptide will be edited out. AT2s from wild-type mice have low expression of CLIP/I-A b complexes, similar to hematopoietic MHCII + lung cells, and in contrast to both cell types from H2-M-deficient mice that have Toulmin, S.A. et al. 8 high levels of CLIP/I-A b (Fig 2e) . Furthermore, the peptide editing activity of H2-M can be antagonized by the protein H2-O 50 . We found that H2-O transcript and protein levels are undetectable in naïve AT2s (Fig S5a,d) . Altogether, these data demonstrate that AT2s express functional H2-M (H2-Mab1) protein.

We also assessed the expression of invariant chain protein and the human H2-Mequivalent, HLA-DM, in human AT2s, by flow cytometry. As in mice, healthy human AT2s expressed both the invariant chain and HLA-DM (Fig S2b) .

Besides extracellular antigens, MHCII also presents peptides derived from intracellular proteins 51-53 . For example, in influenza (flu) virus infections in B6 mice, endogenous MHCII presentation of peptides from viral proteins synthesized within infected cells, instead of engulfed extracellular viral material, drives the majority of the antiviral CD4 + T cell response 54 . Endogenous MHCII presentation involves a heterogenous network of machinery that are less well characterized compared to the classical pathway, precluding an exhaustive study of specific mediators here. However, one prerequisite for endogenous processing is expression of intracellular antigen by the APC. We assessed whether AT2s produce viral proteins intracellularly after exposure to live influenza virus and found that AT2s expressed both hemagglutinin (HA) as well as nucleoprotein (NP) to high levels ( Fig S4) . This suggests that AT2s possess abundant substrate material for endogenous processing during flu infections, and this presumably extends to other respiratory viral infections for which they are also main targets.

Beyond peptide/MHCII complex formation, another component of APC function is the provision of costimulation. In general, priming of naïve T cells requires APC expression of the proteins CD80 or CD86, while the reactivation of effector T cells is less Toulmin, S.A. et al. 9 costimulation-dependent and may be influenced by a wider spectrum of costimulatory molecules 55, 56 . Prior studies indicate that naïve AT2s do not express CD80 or CD86, but that they express the noncanonical costimulatory molecule ICAM-1 [19] [20] [21] . We also assessed AT2s for CD80, CD86, and ICAM-1 expression and found that AT2s expressed ICAM-1, but not CD80 or CD86, both at homeostasis and after influenza infection ( Fig   S5e,f) .

Taken together, these data indicate that AT2s possess the requisite characteristics and intracellular machinery to endow them with MHCII antigen presentation capacity; in combination with the expression of ICAM-1 but not CD80/CD86, this would predict that AT2s have the ability to act as APCs, activating effector, but not naïve, CD4 + T cells that enter the lung.

AT2 MHCII contributes to improved respiratory viral disease outcomes As AT2s express both MHCII and the conventional MHCII-associated APC machinery, we predicted that AT2 MHCII presentation would contribute to immune responses in vivo.

To test this, we generated mice with an AT2-specific deletion of MHCII by breeding mice to have both (1) a tamoxifen-inducible Cre enzyme controlled by the AT2-specific surfactant protein C (SPC) promoter 57 and (2) LoxP sites flanking exon 1 of the I-A b b chain on both alleles 58 (SPC-Cre-ERT2 +/-× H2-Ab1 fl/fl ; aka "SPC DAb1 "). Upon tamoxifen administration, SPC DAb1 mice exhibit uniform deletion of MHCII from AT2s (Fig 3a-c) , in contrast to the parental strains whose AT2s retain MHCII: those expressing the Cre enzyme with a wild-type I-A b locus (SPC-Cre-ERT2 +/only; aka "SPC Cre "), as well as those with homozygous floxed I-A b alleles but no Cre (H2-Ab1 fl/fl only; aka "Ab1 fl/fl "). Toulmin, S.A. et al. 10 To ensure that the deletion of MHCII in SPC DAb1 mice was restricted to AT2s, we compared MHCII on various other APCs in the lungs and spleens of all three strains. Similar frequencies of lung B cells, alveolar macrophages, lung CD103 + DCs, splenic B cells, and splenic CD8a + DCs, expressed MHCII in all three strains, suggesting that the Cre-mediated deletion of MHCII was AT2-specific (Fig 3c) . However, the overall magnitude of MHCII on certain APCs was lower in both the SPC DAb1 and Ab1 fl/fl mice compared to the SPC Cre strain (Fig 3d) ; this suggests that in mice of the H2-Ab1 fl/fl genetic background, the I-A b targeting construct diminishes MHCII expression in some cell types, independent of Cre expression. Based on these data, we considered the Ab1 fl/fl mice the most appropriate comparators for the SPC DAb1 mice, so these two strains were paired for our in vivo studies.

We first assessed whether loss of MHCII on AT2s resulted in lung disease or immune dysfunction at homeostasis. To do so, we compared hematoxylin and eosin (H&E) staining of naïve 12-week-old SPC DAb1 and Ab1 fl/fl lungs. Both strains demonstrated normal, healthy lung architecture with minimal infiltrates (Fig 3e) . We also examined whether SPC DAb1 mice had subclinical alterations in lung immune cells as well as splenic T cells, by flow cytometry. 12-week-old old naïve SPC DAb1 and Ab1 fl/fl lungs and spleens had overall similar frequencies and numbers of CD4 + and CD8 + T cells (Fig 3f, S6 , Table 1 ); both T cell subsets in both organs of the two strains also demonstrated similar expression of memory phenotype markers CD44 and CD62L (Fig   3g, S6) , the proliferation marker Ki-67, and the inhibitory receptor and activation/exhaustion marker PD1 (Fig S6) . Minor differences between SPC DAb1 and Ab1 fl/fl mice achieved statistical significance in the cases of CD4 + T cell numbers, the Toulmin, S.A. et al. 11 proportion of CD4s expressing CD44/CD62L, and the proportions of CD4s and CD8s expressing the activation/exhaustion marker PD1. However, these differences do not result in detectable pathology, as above (Fig 3e) , nor do they appear to influence outcomes following infection, as described below ( Fig S9) . As surface MHCII is the main ligand for the T cell inhibitory receptor LAG3, which restricts T cell expansion and effector function 59 , we also evaluated LAG3-expressing T cells in the lungs and spleen of both strains at homeostasis; we found no differences in the frequencies of LAG3 + CD4 + and Table 2 ). The frequency of lung and splenic Tregs was also similar between SPC DAb1 and Ab1 fl/fl mice (Fig 3h, S6 ). Frequencies of tissue resident-memory CD69 + CD11a + CD4 + and CD69 + CD8 + T cells 60 in the lungs were also similar between the two strains (Fig 3i) , as were the frequencies and numbers of alveolar macrophages, neutrophils, B cells, NK cells, and gdT cells ( Fig S6) . Thus, overall, MHCII appears to be dispensable for the maintenance of a healthy immune environment in the lung at homeostasis in young adult mice. Furthermore, as the SPC DAb1 mice did not experience respiratory disease at homeostasis, and AT2s sorted from SPC DAb1 and Ab1 fl/fl mice formed similar numbers of lung organoids in vitro (Fig S8) , MHCII also does not seem to be required for two main physiologic functions of AT2s: surfactant production and lung regeneration.

We next assessed whether AT2 MHCII contributes to the outcome of lung infection.

To do this, we used two respiratory virus infection models: mouse lung-adapted PR8 influenza A virus (IAV) as well as Sendai virus (SeV), a natural mouse pathogen similar to human parainfluenza virus. To assess the impact of AT2 MHCII on viral disease, we measured weight loss of SPC DAb1 and Ab1 fl/fl mice after infection with either IAV or SeV. Table 3 ). However, after SeV infection, SPC DAb1 mice experienced significantly more weight loss and delayed recovery compared to the Ab1 fl/fl group (Fig 4b; Extended Data Table 4 ). We also assessed the impact of AT2 MHCII on mortality after infection with both viruses. SPC DAb1 mice experienced reduced survival after IAV infection compared to Ab1 fl/fl controls, 24% vs 50% respectively (Fig 4c) . Similarly, after SeV infection, SPC DAb1 mice had worse survival with approximately 2-fold higher mortality (28%) compared to the Ab1 fl/fl controls (12%) (Fig 4d) . We next asked whether AT2 MHCII antigen presentation might contribute to the control of viral replication, by measuring lung virus titers after infection with either IAV or SeV. There were no significant differences in IAV titers 7 days after infection between SPC DAb1 and Ab1 fl/fl mice (Fig 4e) . Similarly, SeV titers 4, 7, and 9 days after infection were similar between the two strains (Fig 4f) . As LAG3 has been shown to restrict lung CD4 + and CD8 + T cell responses during respiratory viral infections 61, 62 , we also considered whether AT2 MHCII is required for LAG3-mediated T cell suppression during infection. We found similar frequencies and numbers of LAG3 + CD4 + and CD8 + T cells in the lungs of SPC DAb1 and Ab1 fl/fl mice 9 days after IAV infection ( Fig   S7) . Thus, while MHCII on AT2s is not required for protection against respiratory viral infection, it does contribute to lower morbidity and mortality, without impacting LAG3 + T cell expansion or lung viral burden.

We also asked whether the minor, yet statistically significant, differences between certain lung T cell subsets in SPC DAb1 and Ab1 fl/fl mice observed at homeostasis were amplified during infection. We observed no statistically significant differences in the numbers of lung CD4 + T cells or the proportion of lung CD4s expressing CD44/CD62L Toulmin, S.A. et al. 13 between SPC DAb1 and Ab1 fl/fl mice 9 days after IAV infection (Fig S9a,b ; Extended Data Table 5 ). Furthermore, the numbers and frequencies of lung CD4 and CD8 T cells expressing the activation/exhaustion marker PD1 were similar (Fig S9c,d) , as was the proportion of AT2s expressing PD-L1, the cognate ligand for PD1 ( Fig S9e) . Thus, the slight differences in magnitude of these T cell subsets at homeostasis are unlikely to explain the differences in outcomes following infection.

In summary, these studies suggest that in vivo in young adult mice, AT2 MHCII expression is dispensable for healthy lung immune homeostasis but confers an appreciable advantage in respiratory viral disease outcome overall.

AT2s exhibit restrained antigen presentation capacity via MHCII Although loss of AT2 MHCII worsened respiratory virus disease, the effect was smaller than anticipated based on the abundance of AT2s in the lung 32 and the magnitude of AT2 MHCII expression. A potential explanation for this more measured impact is that AT2s possess limited MHCII antigen processing and presentation capacity.

To investigate the antigen presentation function of AT2s, we first evaluated the ability of AT2s to stimulate flu peptide/MHCII complex-specific costimulation-independent T cell hybridomas (Fig 5a) . AT2 presentation of five different epitopes from live virus was undetectable (Fig 5b,c) , in contrast to professional APCs that presented all five. Poor presentation by AT2s was not due to a failure of in vitro infection, as AT2s were infected to levels higher than comparator professional APCs (Fig S4a) . Limited presentation was observed across multiple MHCII alleles, B6 I-A b (Fig 5b) and BALB/c I-E d (Fig 5c) , was not the result of protein source, as both neuraminidase (NA) and HA-derived epitopes Toulmin, S.A. et al. 14 were similarly affected (Fig 5b, c) , and was similar for epitopes generated by both exogenous (HA [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] ) and endogenous (NA 79-93 ) processing pathways 63 (Fig 5c) . Even when pulsed with synthetic peptides, AT2s were able to present only three out of five epitopes (HA 91-107 , HA 302-313 , NA 79-93 ) (Fig 5b,c) . Thus, AT2s exhibited a global impairment in the capacity to present MHCII-restricted epitopes in vitro.

Assays of AT2 function in vitro may be suboptimal due to reduced viability after cell sorting and the gradual de-differentiation of AT2s in standard tissue culture 64, 65 .

Additionally, measuring presentation on an individual epitope basis may underestimate the presentation of all possible MHCII-restricted flu peptides. Thus, we next examined AT2 in vivo flu peptide/MHCII complex formation, by co-culturing in vivo-infected AT2s from wild-type or MHCII -/-B6 mice taken 4 days post influenza infection with polyclonal splenic CD4 + or CD8 + T cells taken 9 days post-infection, in the presence of soluble anti-CD28 (Fig 5d) . MHCII presentation was detected via T cell IFNg production captured by ELISpot. AT2s from flu-infected mice were capable of stimulating both CD4 + and CD8 + T cells to produce IFNg (Fig 5e) . Stimulation of CD4 + T cells, but not CD8 + T cells, was abrogated when MHCII -/flu-infected AT2s were used as APCs, confirming that stimulation of CD4 + T cells by AT2s was MHCII-dependent. However, consistent with our in vitro studies, AT2 presentation to CD4 + T cells was markedly less efficient than professional APCs, in this case CD103 + CD11c + cells taken from the same lungs; despite being 9 times more infected, AT2s (99% infected, Fig S4b) stimulated less than half the IFNg production than the comparator APCs (11% infected, Fig S4b) .

We considered that the high degree of AT2 infection in our assays might impair their capacity to process and present antigen. To address this, we measured MHCII antigen Toulmin, S.A. et al. 15 presentation using a non-infectious model system, by staining lungs directly ex vivo with the peptide/MHCII complex-specific "YAe" antibody 66 (Fig 6a) . YAe detects Ea 52-68 /I-A b complexes, which form in [BALB/c x B6] F1 mice as they are composed of a peptide from I-E d (BALB/c-derived) presented by I-A b (B6-derived). In naïve F1 mice, AT2s had low yet detectable YAe staining above the background levels of B6 AT2s (Fig 6b,c) . However, YAe staining of F1 AT2s was significantly lower than that of F1 lung B cells (Fig 6b, c, Extended Data Table 6 ). This could not be explained by differences in expression of the source proteins, I-A b and I-E d , which are similarly expressed by AT2s and B cells at homeostasis, if not slightly higher in AT2s (Fig 6d, To better approximate the setting of viral infection, we also treated mice with IFNg and then measured Ea 52-68 /I-A b complex formation. AT2 YAe staining was significantly increased in F1 mice after treatment with IFNg, but was again lower than B cells in the same mice (Fig 6b,c) . To assess the contributors to increased MHCII presentation in AT2s, we evaluated changes in expression of I-A b , I-E d , and H2-M, all of which are required for Ea 52-68 /I-A b complex formation 67 . Both I-A b and I-E d increased in AT2s after IFNg administration (Fig 6d,e) . IFNg also induced some AT2s to express the H2-Mab2 isoform of H2-M (Fig 6f, g, Extended Data Table 9 ), which is absent at baseline where AT2s express the H2-Mab1 isoform only, as previously demonstrated (Fig 2, S5a) .

Although H2-Mab2 + AT2s exhibited more YAe staining than H2-Mab2 -AT2s, both populations stained highly after IFNg treatment (Fig 6h) , suggesting that a higher magnitude of H2-M contributes to enhanced Ea 52-68 /I-A b presentation, but the specific H2- Toulmin, S.A. et al. 16 Mab2 isoform is not required. Thus, AT2 MHCII presentation increases during IFNg inflammation due to the upregulation of several MHCII presentation mediators, but it is still less efficient than that of professional APCs.

Taken together, these data demonstrate that AT2s are capable of presenting antigen via MHCII to CD4 + T cells, and this is enhanced in the setting of inflammation; however, compared to professional APCs they exhibit limited antigen presentation of MHCIIrestricted epitopes derived from both viral and endogenous proteins, as well as some extracellular peptides. This restrained presentation capacity may explain the variability seen in prior studies of AT2 function owing to differences in the model systems used, in particular the level of antigen provided to the AT2s, as well as the specific epitopes studied.

Here we establish that AT2 cells stand alone in a new category of MHCII-expressing cells, as non-immune cells that nonetheless constitutively express MHCII in an IFNgindependent manner. We demonstrate that AT2 MHCII may contribute to improved outcomes of respiratory virus disease in vivo, and that in contrast to professional APCs, AT2s exhibit a program of restrained MHCII antigen presentation.

We were unable to identify an immune signal required for AT2 MHCII expression despite investigating a variety of broad adaptive and innate mediators, including the microbiota. This suggests that MHCII expression is not driven by inflammation. As AT2

MHCII is upregulated only after birth (J. Whitsett, B. Aronow, S. Potter [CCHMC] and the Toulmin, S.A. et al. 17 LungMAP Consortium [U01HL122638]; single cell RNA-seq data available at www.lungmap.net), its expression may instead be induced by a non-immunologic environmental stimulus or may be an intrinsic part of the AT2 cell developmental identity.

The constitutive nature of AT2 MHCII expression prompted us to also consider whether AT2 MHCII plays a novel, non-immune role in basic AT2 biology. We demonstrated that AT2 MHCII is not required for the regenerative function of AT2s, and as the SPC DAb1 mice exhibit no lung disease either clinically or histologically, it is most likely also dispensable for surfactant production. More extensive characterization of AT2 physiology and function will be needed to investigate whether there are other non-immunologic processes that are disrupted by the loss of MHCII from AT2s.

We demonstrated that inefficient antigen presentation by AT2s cannot be explained by the absence of conventional MHCII-associated machinery. Instead, it is possible that there are mechanisms operating in AT2s that actively oppose MHCII presentation. AT2s possess a highly specialized endosomal network specifically tailored to the synthesis, secretion, and recycling of surfactant proteins and lipids 46 . It is possible that these endocytic compartments are incompatible with the spatiotemporal degradative and peptide loading requirements for MHCII presentation. It is also unusual that AT2s present only some synthetic peptides when provided exogenously. One possible explanation is that AT2 cell surface MHCII molecules are already bound to a high affinity self-peptide that can be displaced only by even higher affinity peptides.

Restrained MHCII antigen presentation by AT2s is consistent with the more measured contribution they make via MHCII to the outcome of lung viral infection. We propose that this limited presentation is favorable in the lung, where excessive T cell activation would Toulmin, S.A. et al. 18 be especially damaging. In this model, high MHCII expression poises AT2s to amplify lung adaptive immune responses, but restricted MHCII presentation establishes a higher threshold that must be overcome in order to do so. This system would allow for a more tempered response, where MHCII presentation by AT2s would be sufficient to trigger cognate T cell activation only in the setting of high antigen burden, such as a severe lung infection, but would prevent AT2-induced amplification of T cells in response to low levels of inhaled innocuous environmental antigens. Ongoing and future work will further explore this possibility.

We found that AT2 MHCII did not affect the total amount of virus in the lung, suggesting that AT2 MHCII contributes to protection by other mechanisms. AT2 MHCII may instead facilitate the development of a protective CD4 + T cell cytokine milieu, which is critical for disease outcome in the setting of respiratory viral infection 68, 69 . CD4 + Tregs have also been demonstrated to facilitate lung repair by enhancing AT2 proliferation 70, 71 . Thus, it is also possible that AT2 MHCII helps to facilitate disease recovery by promoting the expansion or localization of CD4 + Tregs to the regions of the lung experiencing high virus loads, in order to minimize damage and enhance alveolar regeneration.

As lung-resident memory CD4 + (Trm) can mediate protection upon viral challenge 72 and circulating virus-specific memory CD4 + T cells correlate with heterosubtypic protection in humans 73 , in future studies it will be important to address whether AT2 MHCII contributes to the development of virus-specific memory CD4 + T cells. Prior studies from the Swain laboratory suggest that robust influenza-specific memory CD4 + T cell formation requires two cognate TCR-MHCII encounters: the first priming interaction in the lymph node, and a second around days 5-7 post-infection 74, 75 . As MHCII + AT2s are present at Toulmin, S.A. et al. 19 the site of infection with access to both antigen and antigen-specific CD4 + T cells, it is possible that AT2s help to deliver this second checkpoint. It is also possible that local AT2 MHCII antigen presentation helps to facilitate the development and retention of lungresident virus-specific memory CD4 + Trm during infection [76] [77] [78] .

AT2 MHCII may also play an important role in regulating CD4 + T cell-driven lung diseases in response to respiratory allergens, such as in allergic asthma as well as hypersensitivity pneumonitis [79] [80] [81] [82] . We demonstrated that the loss of AT2 MHCII did not result in lung disease at homeostasis in 12-week-old specific pathogen free (SPF) mice, suggesting that AT2 MHCII does not contribute to inhaled antigen tolerance or allergy.

However, as SPF mice experience artificially low levels of antigen exposure, it is possible that the impact of AT2 MHCII loss would be more apparent in mice with a greater burden or longer duration of inhaled putative allergen exposure, such as aged mice or wild mice [83] [84] [85] [86] , or those intentionally sensitized to allergens.

Finally, an essential avenue of future work will also be to understand whether 

The B6 primary skin fibroblast cell line was derived in our laboratory and has been described previously 102 Toulmin, S.A. et al. 22 The following synthetic peptides were used: HA 91 Expression was quantified relative to the housekeeping gene Hprt using the DCT method.

macrophages (CD45 + , CD11c + , CD103 -, CD11b -, CD64 + ), Splenic CD8 + DCs (CD45 + , CD11c + , CD3 -, CD8 + ), B cells (FSC-A low , CD45 + , CD11c -, CD19 + or B220 + ), CD4 + T cells (CD45 + , CD3 + , CD4 + , CD8 -), CD8 + T cells (CD45 + , CD3 + , CD8 + , CD4 -), NK cells (CD45 + , CD3 -, NK1.1 + ),

The following forward (F) and reverse (R) primer pairs were used. H2-Aa F: 

Donor bone marrow was isolated from C57Bl6 MHCII -/and CD45.1 B6 mice, and T cells were depleted magnetically using Thy1.2 Dynabeads (11443D, Thermo Fisher). pathologist. Images were acquired using an Aperio AT2 Slide Scanner (Leica) and evaluated using Aperio ImageScope software (Leica).

For determination of T cell phenotype as well as activation status, cells were surface stained for the following markers: CD44, CD62L, CD69, CD11a, PD1, and LAG3. Cells were also stained intranuclearly for FoxP3 and Ki67.

Alveolar organoids were cultured as described previously 29, 31 , with the following 

Mice were infected intranasally with 3 FFU IAV PR8 diluted in 20 µL PBS under isoflurane anesthesia. Mice were sacrificed 9 days after infection and lungs were stained ex vivo for T cell surface markers and LAG3.

Mice were infected intranasally with 3 FFU IAV PR8 diluted in 20 µL PBS under isoflurane anesthesia. For PD-L1 analysis, mice were sacrificed 9 days after infection and lungs were dissociated for AT2s as above, then stained ex vivo for AT2 cell markers and PD-L1. For PD1, CD44, CD62L analysis, mice were sacrificed 9 days after infection and lungs were dissociated for T cells as above, then stained ex vivo for T cell surface markers, PD1, CD44, and CD62L. IFNg spots were imaged and counted using a CTL ImmunoSpot S6 Universal Analyzer. 

Assay diagrams in Figs 5-6 were adapted from images created with BioRender.com.

All statistical analyses were performed using Prism 8 software ( Figure S7 . Table 3 Figure S9 .

Extended Data Table 6 : Three way ANOVA analysis results for YAe staining.

Results of three-way ANOVA factoring in genotype, treatment (Tx), and cell type as Overall model effects 

Expression regulation of major histocompatibility complex class I and class II encoding genes

Regulation of MHC class II gene expression by the class II transactivator

Role of major histocompatibility complex class II expression by nonhematopoietic cells in autoimmune and inflammatory disorders: facts and fiction

Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell

Innate lymphoid cells regulate CD4+ T-cell responses to intestinal commensal bacteria

Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4(+) T cells

Lymph node stromal cells acquire peptide-MHCII complexes from dendritic cells and induce antigen-specific CD4(+) T cell tolerance

Roles of lymphatic endothelial cells expressing peripheral tissue antigens in CD4 T-cell tolerance induction

Absence of MHC-II expression by lymph node stromal cells results in autoimmunity

Lymph Node Stromal Cells Generate Antigen-Specific Regulatory T Cells and Control Autoreactive T and B Cell Responses

Cutting Edge: Murine Vascular Endothelium Activates and Induces the Generation of Allogeneic CD4+25+Foxp3+ Regulatory T Cells

Interferon-gamma induces expression of MHC class II on intestinal epithelial cells and protects mice from colitis

Epithelial MHC Class II Expression and Its Role in Antigen Presentation in the Gastrointestinal and Respiratory Tracts

MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graftversus-Host Disease and Is Influenced by the Microbiota

Class II molecules on rat alveolar type II epithelial cells

Class II MHC molecules and monocytes/macrophages in the respiratory system of conventional, germ-free and interferon-gamma-treated rats

Primary type II alveolar epithelial cells present microbial antigens to antigenspecific CD4+ T cells

Alveolar Epithelial Type II Cells Induce T Cell Tolerance to Specific Antigen

Alveolar type II epithelial cells present antigen to CD4(+) T cells and induce Foxp3(+) regulatory T cells

Fraction of MHCII and EpCAM expression characterizes distal lung epithelial cells for alveolar type 2 cell isolation

The distribution of MHC class I and II antigens on bronchial epithelium

Isolation and culture of alveolar type II cells

Maintenance of the differentiated type II cell phenotype by culture with an apical air surface

A novel MHC class II epitope expressed in thymic medulla but not cortex

Selection of a broad repertoire of CD4+ T cells in H-2Ma0/0 mice

Influenza virus-specific CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection

Distinct types of lung disease caused by functional subsets of antiviral T cells

Foxp3(+) Regulatory T Cell Expression of Keratinocyte Growth Factor Enhances Lung Epithelial Proliferation

Foxp3+ regulatory T cells promote lung epithelial proliferation

Cutting edge: Tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans

New Insights into the Generation of CD4 Memory May Shape Future Vaccine Strategies for Influenza

Effector CD4 T-cell transition to memory requires late cognate interactions that induce autocrine IL-2

Antiviral B cell and T cell immunity in the lungs

Lung Tissue Resident Memory T-Cells in the Immune Response to Mycobacterium tuberculosis

CD4+ Memory T Cells at Home in the Tissue: Mechanisms for Health and Disease

The immunology of asthma

Hypersensitivity pneumonitis: a complex lung disease

Hypersensitivity pneumonitis: insights in diagnosis and pathobiology

Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis

Environmentally determined differences in the murine lung microbiota and their relation to alveolar architecture

The comparative immunology of wild and laboratory mice, Mus musculus domesticus

Wild Mouse Gut Microbiota Promotes Host Fitness and Improves Disease Resistance

Laboratory mice born to wild mice have natural microbiota and model human immune responses

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues

Mice lacking all conventional MHC class II genes

H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection

Multiple defects of immune cell function in mice with disrupted interferongamma genes

Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease

Mice Lacking the MHC Class II Transactivator (CIITA) Show Tissue-Specific Impairment of MHC

Protective antibodies develop, and murine Lyme arthritis regresses, in the absence of MHC class II and CD4+ T cells

Defective major histocompatibility complex class II assembly, transport, peptide acquisition, and CD4+ T cell selection in mice lacking invariant chain expression

Neutralizing Antibody Responses to Viral Infections Are Linked to the Nonclassical MHC Class II Gene H2-Ob

Immune response in mice that lack the interferon-gamma receptor

Type I IFNs Act upon Hematopoietic Progenitors To Protect and Maintain Hematopoiesis during Pneumocystis Lung Infection in Mice

Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms

Stat6 Is Required for Mediating Responses to IL-4 and for the Development of Th2 Cells

Differential requirements for endosomal reduction in the presentation of two H2-E(d)-restricted epitopes from influenza hemagglutinin

Isolation and culture of human alveolar epithelial progenitor cells

Salmon provides fast and biasaware quantification of transcript expression

Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt

Conventional DCs sample and present myelin antigens in the healthy CNS and allow parenchymal T cell entry to initiate neuroinflammation

Absence of MHC class II on cDC1 dendritic cells triggers fatal autoimmunity to a cross-presented self-antigen

We thank the Children's Hospital of Philadelphia (CHOP) Flow Cytometry Core, in particular F. Tuluc, for their assistance with the flow cytometry and cell sorting experiments. We thank E. Radaelli and the Penn Vet Pathology Core for their help with our tissue histology studies, and we thank A. Stout and the Penn CBD Microscopy Core for their help with imaging. We thank the CHOP Abramson Research Center Animal (Fig S5a) , which was conducted by J.H.L., and the growth of organoids (Fig S8) , which was conducted by A.J.P. L.C.E. 

The authors declare no competing interests. a ! !"#"$ %"&'()*+),#$ -./$ -01$23'$ 4%567 ! $%4$ 4089$4"00$ "#$%! &'()*+)',!-.)+'! /0/$! 1213! 45510! 1%%! "++,)! "&&67! 15! 0! 132! 3! 8097)! :8"&&!;8097<!)=>.)!-.)+'! 1?0/! 51$! 1?$%2! 54! 8097@1! :8"&&!;8097<!@A,)!-.)+'! 14%/! %40! 53452! 52! 809B:)! 809B:!)=>.)!-.)+'! 104! $/2! 0042! 1%! 809B:@1! 809B:!@A,)!1!-.)+'! 15$! 000! 1$/0! 04! 809B:@0! 809B:!@A,